Xanapride 2 Tablet contains Glimepiride 2 mg, an oral hypoglycemic agent belonging to the sulfonylurea class, primarily indicated for the management of type 2 diabetes mellitus. Glimepiride acts by stimulating pancreatic beta cells to release insulin, thereby improving glycemic control in patients with insufficient endogenous insulin production. It also enhances peripheral insulin sensitivity, facilitating glucose uptake in muscle and adipose tissues. Xanapride 2 is typically prescribed as an adjunct to diet and exercise to achieve optimal blood glucose levels. The medication is administered once daily, preferably with breakfast to reduce the risk of hypoglycemia. Patients should be monitored regularly for blood glucose levels, HbA1c, and signs of hypoglycemia, especially during treatment initiation or dose adjustments. Common adverse effects include hypoglycemia, weight gain, and gastrointestinal disturbances. Caution is advised in patients with hepatic or renal impairment, and it is contraindicated in type 1 diabetes, diabetic ketoacidosis, and hypersensitivity to sulfonylureas. Proper patient education on adherence, lifestyle modification, and recognition of hypoglycemic symptoms is essential for effective therapy. Xanapride 2 should be used under medical supervision to ensure safety and efficacy in diabetes management.